Xilio Therapeutics, Inc. (XLO) Fair Value 2026

XLO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-28, Xilio Therapeutics, Inc. (XLO) trades at $9.00. QOC: 5.8/10. Value Trap Risk: 42/100 (WARN). 0/13 models active.

Key Facts

Ticker
XLO
Price
$9.00
Quality Score
5.8/10
Value Trap Risk
42/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give XLO?

0 Intrinsic Value Models vs. Current Price ($9.00)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Xilio Therapeutics, Inc. (XLO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Xilio Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About XLO?

0 of 13 models are currently active for XLO. See which stocks rank higher →

How Does XLO Rank in Biotechnology?

Among 625 Biotechnology stocks, XLO ranks #177 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Xilio Therapeutics, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is XLO a Value Trap?

CirclFi's Value Trap algorithm assigns XLO a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Xilio Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Xilio Therapeutics, Inc.'s fundamental quality profile registers 5.8/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every XLO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Xilio Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BBOTBridgeBio Oncology Therapeutics, Inc.QOC 5.8INBXInhibrx Biosciences, Inc.QOC 5.8CUECue Biopharma, Inc.QOC 5.8ATAIAtaiBeckley Inc.QOC 5.8CCCCC4 Therapeutics, Inc.QOC 5.8OABIOmniAb, Inc.QOC 5.7IPSCCentury Therapeutics, Inc.QOC 4.9INKTMiNK Therapeutics, Inc.QOC 4.3CORTCorcept Therapeutics IncorporatedQOC 8.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BBOT · INBX · CUE · ATAI · CCCC · OABI · IPSC · INKT · CORT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to XLO?

6 companies across all industries closest to XLO’s Quality of Company score of 5.8/10.

CWHCamping World Holdings, Inc.QOC 5.8ALMUAeluma, Inc.QOC 5.8CSWCCapital Southwest CorporationQOC 5.8CYNCyngn Inc.QOC 5.8PRSOPeraso Inc.QOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CWH · ALMU · CSWC · CYN · PRSO · NVDA

Where Does XLO Sit in CirclFi's Biotechnology Rankings?

XLO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Xilio Therapeutics, Inc.’s Valuation?

What is Xilio Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Xilio Therapeutics, Inc. (XLO). The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is XLO overvalued or undervalued right now?

At $9.00, 0 of 0 active models suggest XLO may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Xilio Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.8 mean for XLO?

Xilio Therapeutics, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on XLO?

CirclFi analyzes XLO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is XLO a value trap in 2026?

Xilio Therapeutics, Inc.'s Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Xilio Therapeutics, Inc. (XLO) a Quality of Company score of 5.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/XLO/ · Methodology
Primary sources for this XLO valuation
  • Financial statements: Xilio Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001840233) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for XLO as of ; valuations recomputed .